"Loading Stock Price & Valuation Data ..."
Unlock News Summary by Subscribing to iPick.ai Premium!
Ask anything related to CELC. [ FAQ on what and how to ask] For non-CELC questions, click the logo in the upper-right corner to return to the main page and ask there.
CEO:Mr. Brian F. Sullivan
Headquarter: 16305 36th Avenue North, Suite 100, Minneapolis, MN, United States, 55446
Industry: Biotechnology, Employees: 87
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). It also engages in developing of CELsignia diagnostic platform. The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is based in Minneapolis, Minnesota.
My Watchlist
